secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001651308-25-000057
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene files 2024 STAR annual report; US GAAP revenue $3.81B, gross margin down
--------------------------------------------------------------------------------

- Revenue $3.81B in 2024, up 55% YoY from $2.46B; gross margin 85.1% vs 84.5% prior year.
- China revenue $1.41B (gross margin 62.9%, down from 68.0%); ex-China revenue $2.40B (97.1% vs 98.0%).
- Total R&D expenses $1.95B, up 10% YoY; zanubrutinib R&D $129M, tislelizumab $69M, Bcl-2 $100M.
- Key product sales 5.0M vials in 2024; inventory 2.6M vials as of Dec 31, 2024.
- Differences between PRC GAAP and US GAAP outlined for share-based comp and lease accounting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000057/0001651308-25-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130825000057/bgne-20250428.htm
  HTML page:      https://secwatch.observer/filing/0001651308-25-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer